Feb 1 (Reuters) - Medivir Ab:
* MEDIVIR - MEDIVIR IS IN DISCUSSIONS WITH FDA ON DESIGN OF PIVOTAL PHASE III CTCL STUDY FOR REMETINOSTAT
* MEDIVIR - INTENDS TO EXECUTE A DIRECTED ISSUE OF CLASS B SHARES TO SWEDISH AND INTERNATIONAL QUALIFIED INSTITUTIONAL INVESTORS Source text for Eikon: Further company coverage: (Bengaluru Newsroom)